NGNE Neurogene Inc.
Neurogene Inc. (NGNE) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $1.29 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.3% since its last earnings release on November 9, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Neurogene Inc.
Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders.
Sector
Healthcare
Industry
Biotechnology
Held By 2 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.